HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on UroGen Pharma (NASDAQ:URGN) and maintained a price target of $54.
August 14, 2023 | 10:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UroGen Pharma's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $54 price target.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, the 'Buy' rating and $54 price target from HC Wainwright & Co. suggest a positive outlook for UroGen Pharma, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100